Brief by Shorts91 Newsdesk / 06:36pm on 22 Aug 2024,Thursday Health & Wellness
The NHS in England will not fund Lecanemab, the first drug shown to slow early-stage Alzheimer's, due to cost concerns, according to NICE. While the drug, licensed by MHRA, demonstrated a 25% reduction in cognitive decline over 18 months, NICE argues that its high cost and required intensive monitoring outweigh the benefits. Approximately 70,000 adults in England were potential candidates. Although available privately, Lecanemab's approval in Great Britain contrasts with the European Medicines Agency's rejection. NICE's final decision will follow a public consultation later this year.
